Physician profile
Blake Scheer
NPI 1871585950
$81,168.32
in general payments reported to CMS, 2019-2025
37 companies · $22K in 2025
The $22K reported for 2025 was more than what 94% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,877 · 2020: $4,591 · 2021: $21K · 2022: $9,593 · 2023: $16K · 2024: $2,438 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $8,758 · Consulting Fee: $2,433 · Travel and Lodging: $1,858 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,950.00 |
| Food and Beverage | $8,758.04 |
| Consulting Fee | $2,432.68 |
| Travel and Lodging | $1,857.94 |
| Education | $108.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $42,034.88 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $20,347.14 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Csl Behring | $5,420.51 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Pharming Healthcare, INC. | $4,999.57 | 2019-2025 | Ruconest, Joenja |
| Takeda Pharmaceuticals U.S.A., INC. | $1,143.62 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $1,082.96 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $955.35 | 2019-2025 | Xembify |
| Genzyme Corporation | $889.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $767.23 | 2019-2025 | |
| Genentech USA, INC. | $561.31 | 2019-2025 | Xolair |
| Pfizer INC. | $381.46 | 2019-2025 | |
| Kaleo, INC. | $329.10 | 2019-2023 | Auvi-Q |
| Phadia US INC. | $272.48 | 2019-2024 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $224.78 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $180.14 | 2021-2025 | Orladeyo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $175.72 | 2023-2024 | Ayvakit |
| Shire North American Group INC | $165.55 | 2019 | |
| Octapharma USA, INC. | $125.36 | 2020 | |
| Incyte Corporation | $123.70 | 2023 | Opzelura |
| Amgen INC. | $122.01 | 2022-2025 | Tezspire |
| Leo Pharma INC. | $115.26 | 2022-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $113.85 | 2019-2024 | |
| Kedrion Biopharma, INC. | $105.46 | 2023-2025 | Kedrab, Koate, Gammaked |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.99 | 2019-2021 | |
| Lilly USA, LLC | $73.68 | 2024-2025 | Ebglyss |
| Adma Biomanufacturing LLC | $43.30 | 2024-2025 | |
| Gc Biopharma USA, INC. | $41.02 | 2025 | Alyglo |
| Mylan Specialty L.P. | $39.86 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $38.26 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $35.20 | 2022-2023 | Coagadex, Gammaplex |
| Alk-Abello, INC | $34.42 | 2021-2023 | Grastek, Ragwitek, Odactra |
| Paratek Pharmaceuticals, INC. | $30.96 | 2025 | Xhance |
| Verona Pharma, INC. | $20.44 | 2025 | Ohtuvayre |
| Uswm, LLC | $20.00 | 2021 | |
| Galderma Laboratories, L.P. | $17.46 | 2024 | |
| Hikma Pharmaceuticals USA | $16.83 | 2023 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $15.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Scheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.